dying E-CEL UVEC. Angiocrine technologies have now been awarded 4 out of 4 highly competitive grants: (1) CIRM, (2) SBIR-NIH, (3) SBIR-NCI, and (4) NYSTEM—the latter, $15.8M awarded to Cornell while Angiocrine retains full commercial rights. Other highlights: • Signed a 3-year Corporate Agreement wi